Copyright
©The Author(s) 2024.
World J Gastroenterol. May 21, 2024; 30(19): 2512-2522
Published online May 21, 2024. doi: 10.3748/wjg.v30.i19.2512
Published online May 21, 2024. doi: 10.3748/wjg.v30.i19.2512
Figure 1 Drugs available for systemic therapy classified according to their mechanism of action, indicating by arrows and colors the main drug combinations studied.
1Immunotherapy. PD1: Programmed cell death protein 1; PDL1: Programmed death-ligand 1; CTLA4: Cytotoxic T-lymphocyte associated protein 4; VEGF: Vascular endothelial growth factor.
- Citation: Urquijo-Ponce JJ, Alventosa-Mateu C, Latorre-Sánchez M, Castelló-Miralles I, Diago M. Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma. World J Gastroenterol 2024; 30(19): 2512-2522
- URL: https://www.wjgnet.com/1007-9327/full/v30/i19/2512.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i19.2512